New inhaler hope for COPD patients in early trial

NCT ID NCT07640451

Not yet recruiting Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new inhaled drug called HRS-9821 in people with moderate to severe COPD. About 90 participants will receive either the drug or a placebo for 28 days. The main goal is to see if the drug improves lung function, measured by how much air they can exhale in one second.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-9821 inhalation suspension
What this could lead to: If successful, this could lead to a new inhaled treatment option for people with moderate to severe COPD, potentially improving their lung function and daily breathing.
What could go wrong: This is an early Phase 2 trial with only 90 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

Shanghai Tongji Hospital

Shanghai, Shanghai Municipality, 200065, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.